Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights

Biotech SG&A Expenses: Vericel vs. Wave Life Sciences

__timestampVericel CorporationWave Life Sciences Ltd.
Wednesday, January 1, 2014137740002999000
Thursday, January 1, 20152247900010393000
Friday, January 1, 20162738800015994000
Sunday, January 1, 20173561000026975000
Monday, January 1, 20184900700039509000
Tuesday, January 1, 20196113900048869000
Wednesday, January 1, 20206883600042510000
Friday, January 1, 20219759200046105000
Saturday, January 1, 202210690300050513000
Sunday, January 1, 202312099800051292000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and Wave Life Sciences Ltd. from 2014 to 2023. Over this period, Vericel Corporation's SG&A expenses surged by approximately 780%, starting from $13.8 million in 2014 to a staggering $120.9 million in 2023. In contrast, Wave Life Sciences Ltd. experienced a more modest increase of around 1,610%, from $3 million to $51.3 million. This trend highlights Vericel's aggressive expansion strategy, while Wave Life Sciences maintains a more conservative approach. Understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning. As the biotech industry continues to evolve, monitoring such financial metrics will be key to predicting future growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025